V
Velarion™Intelligence
Sign InFree TrialBook a Walkthrough

89bio Executive Compensation (FY24)

ETNB · Executive and director compensation, fiscal 2022 to 2024

The paid brief on 89bio

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Data as of September 7, 2026Latest filing (DEF 14A): April 15, 2025
3 filings cited on this page
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
89bio brief$1,500Get the executive brief
240 figures on this page, cited to the filing that reported them. See the citations
Chief executive, fiscal 2024
◇
Rohan Palekar
Chief executive pay ratio
◇
To the median employee

More on 89bio

Five data products on this company. Each one is requested through the developer setup page.
What changed from fiscal 2023 to fiscal 2024
The figures that moved, and by how much. Analysis of these figures is part of the Velarion platform.
Chief executive total compensation — Rohan Palekar: $5,587,661 → $7,619,426 (36.4% higher)

Frequently asked questions

Answers drawn from the data on this page.
Who is 89bio's chief executive and what were they paid?
Total compensation for Rohan Palekar, Chief Executive Officer and Director, came to $7,619,426 in fiscal 2024. Compared with the $5,587,661 reported for fiscal 2023, Palekar's total was 36.4% higher.
Which companies are in 89bio's peer group?
The disclosed peer group names Akero Therapeutics, Arrowhead Pharmaceuticals, Cytokinetics, Denali Therapeutics and Immunovant, among others.
What is 89bio's chief executive pay ratio?
For fiscal 2024, the company reported a chief executive pay ratio of 19:1, against median employee compensation of $396,532.

Executive compensation

Every element reported for each named executive officer, by fiscal year.
Fiscal 2022
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rohan Palekar
Chief Executive Officer
◇—◇◇◇—◇◇
Hank Mansbach
Chief Medical Officer
◇—◇◇◇—◇◇
Quoc Le-Nguyen
Chief Technical Operations Officer
◇—◇◇◇—◇◇
Fiscal 2023
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rohan Palekar
Chief Executive Officer
◇—◇◇◇—◇◇
Hank Mansbach
Chief Medical Officer
◇—◇◇◇—◇◇
Quoc Le-Nguyen
Chief Technical Operations Officer
◇—◇◇◇—◇◇
Fiscal 2024
OfficerSalaryBonusStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Rohan Palekar
Chief Executive Officer and Director
◇—◇◇◇—◇◇
Hank Mansbach
Chief Medical Officer
◇—◇◇◇—◇◇
Quoc Le-Nguyen
Chief Technical Operations Officer
◇—◇◇◇—◇◇
Ryan Martins
Chief Financial Officer
◇—◇◇◇—◇◇
Francis Sarena
Chief Operating Officer
◇—◇◇◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. A negative change in pension value is shown but, as the company reports it, not included in the total.

Equity awards granted

Individual awards as disclosed: type, date, unit counts at each level, and grant date value.
Fiscal 2024
OfficerAwardGrant dateThreshold unitsTarget unitsUnits grantedMaximum unitsExercise priceGrant date fair value
Francis SarenaOPTION◇——◇—◇◇
Francis SarenaRSU◇——◇——◇
Hank MansbachOPTION◇——◇—◇◇
Hank MansbachRSU◇——◇——◇
Hank MansbachPSU◇—◇—◇—◇
Hank MansbachRSU◇——◇——◇
Quoc Le-NguyenRSU◇——◇——◇
Quoc Le-NguyenOPTION◇——◇—◇◇
Quoc Le-NguyenRSU◇——◇——◇
Quoc Le-NguyenPSU◇—◇—◇—◇
Rohan PalekarRSU◇——◇——◇
Rohan PalekarOPTION◇——◇—◇◇
Rohan PalekarPSU◇—◇—◇—◇
Ryan MartinsRSU◇——◇——◇
Ryan MartinsPSU◇—◇—◇—◇
Ryan MartinsRSU◇——◇——◇
Ryan MartinsOPTION◇——◇—◇◇
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero. Threshold, target and maximum apply only to performance awards and are never shown for time-based or option awards.

Outstanding awards

Awards still held at fiscal year end.
As disclosed at fiscal 2024 year end
OfficerAwardUnvested unitsMarket value of unvested unitsExercise priceExpires
Ryan MartinsRSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
PSU◇◇——
RSU◇◇——
PSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Hank MansbachRSU◇◇——
RSU◇◇——
Option◇—◇—
PSU◇◇——
RSU◇◇——
Option◇—◇—
RSU◇◇——
Option◇—◇—
Option◇—◇—
Quoc Le-NguyenPSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
RSU◇◇——
RSU◇◇——
RSU◇◇——
RSU◇◇——
Rohan PalekarRSU◇◇——
PSU◇◇——
PSU◇◇——
RSU◇◇——
RSU◇◇——
Option◇—◇—
Option◇—◇—
Option◇—◇—
Option◇—◇—
Francis SarenaRSU◇◇——
Option◇—◇—
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director compensation

What each non-employee director was paid.
Fiscal 2024
DirectorFees earned in cashStock awardsOption awardsNon-equity incentivePension and deferred earningsAll other compensationTotal
Martin Babler
◇—◇———◇
Charles McWherter
◇—◇———◇
Steven M. Altschuler
Board chair
◇—◇———◇
Lota Zoth
◇—◇———◇
Kathleen D. LaPorte
◇—◇———◇
Michael Hayden
◇—◇———◇
Edward Morrow Atkinson III
◇—◇———◇
Derek DiRocco
◇—◇———◇
Rohan Palekar served on the board in fiscal 2024 and received no compensation for board service. Executive directors are typically paid through their executive roles, shown above.
A dash means the company reported no figure in that column. $0 is shown only where the filing prints a zero.

Director fee schedule

The standing retainers and premiums the board pays, as published.
Board cash retainer◇
Total board retainer◇
Board chair premium◇
Audit committee chair◇
Audit committee member◇
Compensation committee chair◇
Compensation committee member◇
Nominating and governance chair◇
Nominating and governance member◇
Equity is delivered as Options.

Disclosed peer group

The companies this board named as its compensation comparison group. The list is disclosure; the comparison is analysis.
Fiscal 2024
  • Akero Therapeutics AKRO
  • Arrowhead Pharmaceuticals ARWR
  • Cytokinetics CYTK
  • Denali Therapeutics DNLI
  • Immunovant IMVT
  • KalVista Pharmaceuticals KALV
  • Madrigal Pharmaceuticals MDGL
  • Mirum Pharmaceuticals MIRM
  • Pliant Therapeutics PLRX
  • Protagonist Therapeutics PTGX
  • RAPT Therapeutics RAPT
  • Terns Pharmaceuticals TERN
  • Ventyx Biosciences VTYX
  • Vera Therapeutics VERA
  • Viking Therapeutics VKTX

Chief executive pay ratio

As calculated and reported by the company.
Ratio
◇
Median employee compensation
◇
Chief executive total compensation
◇
Email me this page as a cited PDF
The same figures, the same citations, formatted to hand to a committee. Nothing is added that is not on this page.
Your address is used for this and nothing else. Unsubscribe in one click.
Tell me when 89bio files
You get a note when this company’s compensation data changes.
Your address is used for this and nothing else. Unsubscribe in one click.

What this page does not include

Everything above is a fact 89bio disclosed, and it is free. Everything below is our analysis of those facts, and it is not.
Peer benchmarking
Where 89bio sits against its disclosed peers — percentile position by role and by pay element, and the ranking behind it. The disclosed peer group is free; comparisons across it are part of the Velarion platform.
Executive Compensation Report — $1,500
Written compensation analysis
A read of the pay program as designed and as paid: incentive structure, goal rigor, the alignment between the committee's stated philosophy and what the numbers show.
Executive Compensation Report — $1,500
Board and governance analysis
Committee composition, independence, director pay positioning, and the governance provisions read together rather than listed.
Board Governance Report — $1,200
Realizable pay
What the awards above are actually worth today against what they were valued at on grant, and what the gap says about the pay-for-performance link.
Velarion Intelligence
Adviser switching and vote outcomes
Two datasets covering compensation-adviser changes and what followed a contested vote. Both are part of the Velarion platform.
Inquire about access
Multiple companies at once
Cross-company views, cohort screens, and data export across the industries we cover. This page is one company; the platform is all of them.
Velarion Intelligence
Join the list for a Velarion Pro seat
Full platform access for one person: every industry we cover, peer positioning, and the written analysis. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.
Join the list for Peer Group Review
Whether 89bio's disclosed peer group is defensible, who names 89bio back in their own benchmarking group, and how pay tracks performance across it. This is the analysis a compensation consultant delivers on the group above. We will email you when it opens.
Your address is used for this and nothing else. Unsubscribe in one click.

Citations

Every figure on this page is cited to the document that reported it. Select any figure to see its citation.
240 figures on this page, cited to the filing that reported them.
240 cited to the filing

Documents cited

  1. 0001193125-25-081504
    2024 Summary Compensation Table · ADVISORY VOTE ON EXECUTIVE COMPENSATION · CEO Pay Ratio · Fiscal Year 2024 Non-Employee Director Compensation Table · and 2 more sections
  2. 0001193125-24-099113
    2023 Summary Compensation Table
  3. 0001193125-23-112935
    2022 Summary Compensation Table
Cite this data
This page is free to cite. Attribution we ask for:
Velarion, “89bio executive compensation, FY2022–FY2024.” https://intel.velarion.ai/comp/ETNB (accessed 2026).
Short form: data: Velarion

The paid brief for 89bio

Positioning against its disclosed peers, the governance read, incentive design, and the CD&A alignment analysis; the full peer table; a committee-ready PDF.
From $1,200 for the board report; $2,400 for both.
Get the executive briefGet the board briefNo account needed.
3 filings cited on this page
Method: intel.velarion.ai/methodology
A report that fails to generate is refunded in full
Published by Velarion Company Intelligence
Embed this data
A small, cited view of this data for your own page or newsletter. Every embed carries a visible link back here, so the attribution travels with it.
The headline figures, each with its citation.
Connect an AI assistant
Ask your own assistant about 89bio and roughly 3,000 other US public companies, and get back the same figures on this page with the same citations. Free read access, no account. Add this to your assistant's connector settings.
Setup guide and the full list of questions it answers

Peers 89bio discloses

The companies named in ETNB's own disclosed peer group.

Akero TherapeuticsArrowhead PharmaceuticalsCytokineticsDenali TherapeuticsImmunovantKalVista PharmaceuticalsMadrigal PharmaceuticalsMirum PharmaceuticalsPliant TherapeuticsProtagonist TherapeuticsRAPT TherapeuticsTerns PharmaceuticalsVera TherapeuticsViking Therapeutics

Terms on this page

Say-on-Pay VoteCEO Pay RatioMedian Employee CompensationAll companies

Free to read and cite. Redistribution or bulk use of the dataset requires a data license. Talk to us about the data license.

Cite this data
APA
Velarion Company Intelligence. (2026). Velarion database: executive and board compensation data (Version 2026Q3) [Data set]. Zenodo. https://doi.org/10.5281/zenodo.22283854
BibTeX
@misc{velarionData2026,
  author = {{Velarion Company Intelligence}},
  title = {Velarion database: executive and board compensation data},
  year = {2026},
  version = {2026Q3},
  doi = {10.5281/zenodo.22283854},
  publisher = {Zenodo},
  url = {https://doi.org/10.5281/zenodo.22283854}
}
For informational purposes only. Not investment, legal, or compensation advice.  All companies · The Pay Desk · Methodology · Terms · Privacy